David Nikodem Ph.D

David Nikodem Ph.D General Information

Biography

Dr. David Nikodem served as a Board Member at Alzheon. Dr. Nikodem served as Chief Executive Officer and Board Member at AltheaDx. Dr. Nikodem served as Managing Director and Head of Biopharma Investments at Ally Bridge Group. He was a Board Member at Tunitas Therapeutics. As a senior representative of Ally Bridge Group ("ABG"), Dr. Nikodem plays an important role in ABG's biopharmaceutical investments and serves on the boards of several of ABG's U.S.-based biopharmaceutical companies. He served as a Board Member at LoneStar Heart. Dr. Nikodem has more than 13 years of experience in capital markets and financial analysis of biotechnology and healthcare companies. Before joining ABG in 2013, Dr. Nikodem served as Portfolio Manager at Exane Asset Management where he managed a global healthcare fund. He also managed a U.S.-focused healthcare fund as a Director at BNP Paribas in New York on the long/short proprietary trading desk. During his seven years as a Portfolio Manager in the healthcare industry, Dr. Nikodem covered a diversified range of healthcare subsectors for public equities and was involved with numerous private deals. Dr. Nikodem began his Wall Street career as a biotechnology analyst at Orbitex Asset Management in 2001, followed by analyst roles at Acacia Research Investment Corporation and Blumberg Capital Management. From 1991 to 1999, Dr. Nikodem conducted basic science research at the National Institutes of Health as well as at Georgetown University, where he earned his Ph.D. in molecular biology. From 1999 to 2001, Dr. Nikodem was a patent examiner at the United States Patent and Trademark Office in Washington, D.C. Dr. Nikodem holds undergraduate degrees in Chemistry and English Language and Literature from the University of Virginia.